JP2016175913A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016175913A5 JP2016175913A5 JP2016078990A JP2016078990A JP2016175913A5 JP 2016175913 A5 JP2016175913 A5 JP 2016175913A5 JP 2016078990 A JP2016078990 A JP 2016078990A JP 2016078990 A JP2016078990 A JP 2016078990A JP 2016175913 A5 JP2016175913 A5 JP 2016175913A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- domain
- seq
- mouse
- modified human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims 12
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 4
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000001772 anti-angiogenic effect Effects 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000004528 endothelial cell apoptotic process Effects 0.000 claims 1
- 150000004676 glycans Chemical group 0.000 claims 1
- 230000005660 hydrophilic surface Effects 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 230000005661 hydrophobic surface Effects 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36393310P | 2010-07-13 | 2010-07-13 | |
| US61/363,933 | 2010-07-13 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013519804A Division JP6353654B2 (ja) | 2010-07-13 | 2011-07-13 | 抗血管新生剤及びこのような薬剤の使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016175913A JP2016175913A (ja) | 2016-10-06 |
| JP2016175913A5 true JP2016175913A5 (cg-RX-API-DMAC7.html) | 2017-02-16 |
Family
ID=44629339
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013519804A Active JP6353654B2 (ja) | 2010-07-13 | 2011-07-13 | 抗血管新生剤及びこのような薬剤の使用方法 |
| JP2016078990A Pending JP2016175913A (ja) | 2010-07-13 | 2016-04-11 | 抗血管新生剤及びこのような薬剤の使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013519804A Active JP6353654B2 (ja) | 2010-07-13 | 2011-07-13 | 抗血管新生剤及びこのような薬剤の使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9175063B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2593127B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6353654B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN103002904B (cg-RX-API-DMAC7.html) |
| AU (5) | AU2011279155B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2804753C (cg-RX-API-DMAC7.html) |
| DK (1) | DK2593127T3 (cg-RX-API-DMAC7.html) |
| ES (2) | ES2674409T3 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE040205T2 (cg-RX-API-DMAC7.html) |
| PL (1) | PL2593127T3 (cg-RX-API-DMAC7.html) |
| PT (2) | PT2593127T (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012009471A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2593127T (pt) * | 2010-07-13 | 2018-07-06 | Georgia State Univ Research Foundation | Agente antiangiogénico e método de usar esses agente |
| WO2016144815A1 (en) * | 2015-03-06 | 2016-09-15 | Georgia State University Research Foundation, Inc. | Integrin-targeting protein and methods of use thereof |
| CN110498851B (zh) * | 2015-11-10 | 2022-10-11 | 孙嘉琳 | 一种抗肿瘤蛋白内皮抑素的衍生物及应用 |
| CN108148117A (zh) * | 2017-12-26 | 2018-06-12 | 张艳雪 | 一种抗菌肽的蛋白质结构特性及其研究方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990008187A1 (en) * | 1989-01-19 | 1990-07-26 | Dana Farber Cancer Institute | Soluble two domain cd2 protein |
| US6162432A (en) * | 1991-10-07 | 2000-12-19 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| EP1539234A4 (en) * | 2002-09-05 | 2006-02-15 | Medimmune Inc | METHOD FOR PREVENTING OR TREATING CELL MALIGNITY BY ADMINISTERING CD2 ANTAGONISTS |
| BRPI0507404A (pt) * | 2004-02-06 | 2007-06-26 | Astellas Us Llc | método de tratamento de um indivìduo que tem psorìase e kit |
| US9339559B2 (en) * | 2005-09-09 | 2016-05-17 | Georgia State University Research Foundation, Inc. | Targeted contrast agents and methods for targeting contrast agents |
| US20110097742A1 (en) * | 2008-04-02 | 2011-04-28 | Jenny Jie Yang | Contrast agents, methods for preparing contrast agents, and methods of imaging |
| US8540967B2 (en) * | 2008-09-08 | 2013-09-24 | Hoffman/Barrett, L.L.C. | Porphyrazine optical and dual optical/MR contrast and therapeutic agents |
| PT2593127T (pt) * | 2010-07-13 | 2018-07-06 | Georgia State Univ Research Foundation | Agente antiangiogénico e método de usar esses agente |
-
2011
- 2011-07-13 PT PT117385468T patent/PT2593127T/pt unknown
- 2011-07-13 HU HUE11738546A patent/HUE040205T2/hu unknown
- 2011-07-13 US US13/739,241 patent/US9175063B2/en active Active
- 2011-07-13 PT PT181685983T patent/PT3381462T/pt unknown
- 2011-07-13 EP EP11738546.8A patent/EP2593127B1/en active Active
- 2011-07-13 PL PL11738546T patent/PL2593127T3/pl unknown
- 2011-07-13 WO PCT/US2011/043907 patent/WO2012009471A1/en not_active Ceased
- 2011-07-13 AU AU2011279155A patent/AU2011279155B2/en active Active
- 2011-07-13 DK DK11738546.8T patent/DK2593127T3/en active
- 2011-07-13 CA CA2804753A patent/CA2804753C/en active Active
- 2011-07-13 ES ES11738546.8T patent/ES2674409T3/es active Active
- 2011-07-13 JP JP2013519804A patent/JP6353654B2/ja active Active
- 2011-07-13 EP EP18168598.3A patent/EP3381462B1/en active Active
- 2011-07-13 CN CN201180034591.9A patent/CN103002904B/zh active Active
- 2011-07-13 ES ES18168598T patent/ES2923430T3/es active Active
-
2015
- 2015-10-30 US US14/928,890 patent/US11578114B2/en active Active
-
2016
- 2016-04-11 JP JP2016078990A patent/JP2016175913A/ja active Pending
-
2017
- 2017-02-20 AU AU2017201133A patent/AU2017201133A1/en not_active Abandoned
-
2019
- 2019-03-29 AU AU2019202174A patent/AU2019202174B2/en active Active
-
2021
- 2021-02-24 AU AU2021201207A patent/AU2021201207A1/en not_active Abandoned
-
2023
- 2023-04-26 AU AU2023202513A patent/AU2023202513A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL253187B (en) | Novel multivalent nanoparticle-based vaccines | |
| Liu et al. | Use of baculovirus expression system for generation of virus-like particles: successes and challenges | |
| JP2016175913A5 (cg-RX-API-DMAC7.html) | ||
| WO2014018858A3 (en) | Multimeric fusion protein vaccine and immunotherapeutic | |
| WO2013044203A3 (en) | Novel influenza hemagglutinin protein-based vaccines | |
| WO2014160490A8 (en) | Antibody formulations | |
| IL278014B1 (en) | Anti-myostatin antibodies, polypeptides containing variable fc regions and methods of use | |
| BR112014019901A8 (pt) | Proteínas de fator viii recombinante | |
| JP2013172734A5 (cg-RX-API-DMAC7.html) | ||
| IN2015DN02546A (cg-RX-API-DMAC7.html) | ||
| BR112014020694A2 (pt) | proteína de fusão do fator viii compreendendo polipeptídeo do fator viii fusionado a polipeptí-deo recombinante estendido (xten) e seu método de fabricação, ácido nucleico, vetores, célula hospedeira, bem como composição farmacêutica e seu uso no tratamento de coagulopatia, episódio de hemorragia e hemofilia a | |
| NZ725079A (en) | Transgene genetic tags and methods of use | |
| EA201591287A1 (ru) | Вакцины, содержащие стабилизированные тримеры оболочки вируса иммунодефицита человека, и способы их применения | |
| MX389878B (es) | Proteinas quimericas de factor viii y usos de estas. | |
| EP2829550A3 (en) | Fusion proteins forming trimers | |
| JP2016501829A5 (cg-RX-API-DMAC7.html) | ||
| EA201692359A1 (ru) | Композиция на основе нового штамма prrsv или его белков, продукт, их применение, вирус prrsv, выделенная нк и рекомбинантный вектор экспрессии для получения этого вируса | |
| EP3308798A3 (en) | Polypeptides and antibodies for treating hbv infection and related diseases | |
| RU2015155821A (ru) | Вакцины против малярии | |
| WO2013096866A3 (en) | Processes using vlps with capsids resistant to hydrolases | |
| HRP20191166T1 (hr) | Stabilizirani proteini, namijenjeni imuniziranju protiv bakterije staphylococcus aureus | |
| WO2015195218A8 (en) | Polyvalent influenza virus-like particles (vlps) and use as vaccines | |
| MX2016009149A (es) | Variantes mejoradas de enzimas. | |
| WO2018020324A3 (en) | Virus-like particles with high-density coating for inducing the expression of antibodies | |
| JP2015511599A5 (cg-RX-API-DMAC7.html) |